Biological soil crust

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Tuesday, March 21, 2023
Inflammation, Skin infection, Siliceous ooze, Civil service commission, Regeneron Pharmaceuticals, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, GPER, TCS, Pain, Heart, European Commission, Patient, Risk, Child, Biological soil crust, European, International development, Growth, Infant, Immunology, Ageing, MPH, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Copper, EU, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Key Points: 
  • “I’ve personally witnessed how this chronic skin disease can disrupt the lives of entire families when left uncontrolled.
  • Between 85% and 90% of patients first develop symptoms before 5 years of age, which can often continue through adulthood.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • “Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

Retrieved on: 
Tuesday, March 21, 2023
Skin infection, Siliceous ooze, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, European Commission, TCS, Pain, Patient, Risk, Child, Biological soil crust, European, Growth, Infant, Ageing, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Copper, EU, Dupilumab

The European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

Key Points: 
  • The European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • With this latest approval, Dupixent is the first-ever biologic medicine for people living with atopic dermatitis from infancy to adulthood.
  • Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Friday, January 27, 2023
European Directive on Traditional Herbal Medicinal Products, Food, Safety, Conjunctivitis, Red, European Commission, Eosinophilia, Caregiver, Quality of life, Risk, CHMP, Patient, Union, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, TCS, Atopic dermatitis, Regeneron Pharmaceuticals, Siliceous ooze, European Medicines Agency, Growth, Biological soil crust, Skin infection, Pain, Birth control, Vaccine, EU, Sanofi, Lancet, Dupilumab

TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent® (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.

Key Points: 
  • The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
  • In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • The use of Dupixent in infants and young children less than 6 years of age with severe atopic dermatitis is investigational in the EU and is not yet approved.

Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Retrieved on: 
Friday, January 27, 2023
European Directive on Traditional Herbal Medicinal Products, Food, Safety, Conjunctivitis, Red, European Commission, Eosinophilia, Caregiver, Quality of life, Risk, CHMP, Patient, Union, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, TCS, Atopic dermatitis, Siliceous ooze, European Medicines Agency, Growth, Biological soil crust, Skin infection, Pain, Birth control, Vaccine, EU, Lancet, Dupilumab

The European Commission is expected to announce a final decision on the Dupixent application in the coming months.

Key Points: 
  • The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
  • In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • The use of Dupixent in infants and young children less than 6 years of age with severe atopic dermatitis is investigational in the EU and is not yet approved.

Messer Converts Chilling and Freezing Lines to Liquid Nitrogen, Improves Cryogen Supply

Retrieved on: 
Tuesday, November 30, 2021
IPPE, Health, Adoption, Ice, Safety, Technology, Industry, Nitrogen, USD, Chill, COVID-19, LIN, Crossflow, Freezing, South America, View, Southern International Productions, Wave, CO2, Food safety, Carbon dioxide, Multimedia, IQF, Biological soil crust, Agitation, Industrial gas

As consumer demand shifts to retail channels, the cryogenic technologies are boosting production of existing processing lines and quickly adding capacity to new lines.

Key Points: 
  • As consumer demand shifts to retail channels, the cryogenic technologies are boosting production of existing processing lines and quickly adding capacity to new lines.
  • In addition, due to the reduced availability of carbon dioxide (CO2), Messer is converting customers to liquid nitrogen (LIN) and thus improving their security of supply.
  • Messer will showcase these proven technologies at the 2022 International Production & Processing Expo (IPPE), Booth C11529.
  • At the Messer Technical Innovation Center in Cleveland, Ohio, product testing can help define optimum chilling, crusting or freezing parameters and validate equipment performance.

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Retrieved on: 
Monday, August 30, 2021
Population, Atopic dermatitis, Quality of life, Skin, Growth, Life, Biological soil crust, Immune system, Sleep, Infection, Parent, Physician, Siliceous ooze, Regeneron Pharmaceuticals, Disease, Human, Skin infection, Ageing, Psoriasis Area and Severity Index, Asthma, Profile, Child, Chlorine, Itch, Safety, Risk, Patient, Caregiver, AD, Â, TCS, IGA, Bath, Vaccine

Dupixent is the first biologic medicine to show positive results in this young population and remains the only approved biologic medicine in patients 6 years and older with uncontrolled moderate-to-severe atopic dermatitis.

Key Points: 
  • Dupixent is the first biologic medicine to show positive results in this young population and remains the only approved biologic medicine in patients 6 years and older with uncontrolled moderate-to-severe atopic dermatitis.
  • When a child is diagnosed with moderate-to-severe atopic dermatitis in the first few months of life, many aspects of their childhood can be significantly impacted.
  • Atopic dermatitis is a chronic type 2 inflammatory disease, with the age of onset younger than 5 years in 85-90% of patients.
  • Moderate-to-severe atopic dermatitis significantly impacts the life of a young child, their parents and caregivers, including their mood, sleep patterns, and quality of life.